Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. Age 18 through 50 years on Study Day 0~3. Completed wriiten Informed Consent~4. BCG vaccination at least 5 years ago,~5. General good health, confirmed by medical history~6. (BMI) between 19 and 33 (kg/m2)~7. Has ability to complete follow-up period of 182 days as required~8. Females must be physically incapable of conception~9. Avoiding elective surgery for the duration of the study~10. Stay in contact with the investigative site for the duration of the study~11. Complete simultaneous enrollment in Aeras Vaccine Development Registry protocol~Exclusion Criteria:~1. Acute illness on the day of randomization~2. Oral temperature \>=37.5 degree Celcius on the day of randomization~3. Evidence of significant active infection~4. Used immunosuppressive medication within 42 days before entry into the study~5. Received immunoglobulin or blood products within 42 days before entry into the study~6. Received any investigational drug therapy or investigational vaccine within 182 days~7. Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study.~8. Current chronic drug therapy including hormone replacement such as thyroxin, insulin, etc.~9. History or laboratory evidence of any past, present or future possible immunodeficiency state which will include any laboratory indication of virus type 1 (HIV-1) infection~10. History of allergic disease or reactions, including eczema.~11. Previous medical history that may compromise safety of subject~12. Evidence of new acute illness that may compromise safety of subject~13. Evidence of chronic hepatitis~14. Inability to discontinue daily medication except contraception~15. History of alcohol or drug abuse within 2yrs~16. Tobacco or cannabis smoking three~17. Positive urine test for illicit drugs~18. History or evidence of any systemic disease on physical examination~19. History of active TB~20. Shared residence within 1 year with an individual on anti-TB treatment~21. All females: nursing~22. Abnormal hemoglobin,hematocrit etc drawn within 36 hours prior to randomization~23. Laboratory test evidence of Mtb infection~24. History of positive tuberculin skin test within past 10 years~25. Received a tuberculin skin test within 3 years~26. History of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- AERAS-404(50mcg H4/0nmol IC31) or Placebo (Type: EXPERIMENTAL): 1 dose
- AERAS404 (50mcgH4/100nmol IC31) or Placebo (Type: EXPERIMENTAL): 1 dose
- AERAS404 (50mcgH4/0nmol IC31) or Placebo (Type: EXPERIMENTAL): 2 dose
- AERAS404 (150mcgH4/0nmol IC31) or Placebo (Type: EXPERIMENTAL): 1 dose
- AERAS404 (50mcgH4/5000nmol IC31) or Placebo (Type: EXPERIMENTAL): 1 dose
- AERAS404 (50mcgH4/500nmol IC31) or Placebo (Type: EXPERIMENTAL): 2 dose
- AERAS404 (Type: EXPERIMENTAL): 2 dose placebo
- AERAS404 (50mcg H4/100nmol IC31) or Placebo (Type: EXPERIMENTAL): 2 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete